 <h1>Khedezla Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>desvenlafaxine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about desvenlafaxine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Khedezla.</p><h2>In Summary</h2><p><b>Common side effects of Khedezla include:</b> constipation, dizziness, drowsiness, insomnia, nausea, decreased appetite, hyperhidrosis, and xerostomia. <b>Other side effects include:</b> anxiety, blurred vision, mydriasis, tremor, vertigo, vomiting, abnormal dreams, chills, and yawning.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to desvenlafaxine: oral tablet extended release</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet, Extended Release)</p><p>Antidepressant use has been associated with an increased risk of suicidal thinking and behavior in children, adolescents, and young adults. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared with placebo in adults aged 65 or older. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Desvenlafaxine is not approved for use in pediatric patients.</p><p class="blackboxWarning-title">Oral route (Tablet, Extended Release)</p><p>Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults during short-term studies. These studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years, and there was a reduction in risk with antidepressants compared with placebo in adults aged 65 or older. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, desvenlafaxine (the active ingredient contained in Khedezla) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking desvenlafaxine:</p><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fast, pounding, or irregular pulse</li>
<li>headache</li>
<li>numbness or tingling in the arms or legs</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>trouble thinking, speaking, or walking</li>
<li>weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>blood in the stool or urine</li>
<li>chest tightness, discomfort, or pain</li>
<li>cough</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>dilated or enlarged pupils (black part of the eye)</li>
<li>dizziness</li>
<li>feeling irritated</li>
<li>fainting</li>
<li>fast, irregular, or pounding heartbeat</li>
<li>fever</li>
<li>hives, itching, or rash</li>
<li>hoarseness</li>
<li>indigestion</li>
<li>joint pain, stiffness, or swelling</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>loss of appetite</li>
<li>loss of bladder control</li>
<li>muscle pain</li>
<li>muscle spasm or jerking of all extremities</li>
<li>nausea</li>
<li>nosebleeds</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>red skin</li>
<li>seizures</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>sudden loss of consciousness</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>talking, feeling, or acting with excitement</li>
<li>trouble breathing or swallowing</li>
<li>unusual bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>vomiting blood</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking desvenlafaxine:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Agitation</li>
<li>bloating</li>
<li>dark urine</li>
<li>feeling of constant movement of self or surroundings</li>
<li>irregular heartbeat recurrent</li>
<li>light-colored stools</li>
<li>muscle cramp or stiffness</li>
<li>nausea</li>
<li>overactive reflexes</li>
<li>poor coordination</li>
<li>restlessness</li>
<li>seizures</li>
<li>sensation of spinning</li>
<li>shivering</li>
<li>stomach pain</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of desvenlafaxine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Decreased appetite</li>
<li>inability to have an orgasm</li>
<li>inability to have or keep an erection</li>
<li>increased sensitivity of the eyes to light</li>
<li>loss of sexual ability, desire, drive, or performance</li>
<li>sleepiness or unusual drowsiness</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Change in taste</li>
<li>continuous ringing, buzzing, or other unexplained noise in the ears</li>
<li>decreased weight</li>
<li>difficult urination</li>
<li>fear or nervousness</li>
<li>hearing loss</li>
<li>jitteriness</li>
<li>lack or loss of strength</li>
<li>loss of taste</li>
</ul><p>
<!-- end oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to desvenlafaxine: oral tablet extended release</i></p><h3>General</h3><p>The most commonly reported side effects were nausea, dry mouth, hyperhidrosis, and dizziness.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Very Common (10% or more): Nausea (up to 36%), dry mouth (up to 25%), constipation (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea, vomiting</p>
<p><b>Rare</b> (less than 0.1%): Acute pancreatitis</p>
<p><b>Frequency not reported</b>: Gastrointestinal bleeding<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Very Common (10% or more): Hyperhidrosis (up to 21%)</p>
<p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia</p>
<p><b>Rare</b> (less than 0.1%): Photosensitivity reaction, Stevens-Johnson syndrome</p>
<p><b>Frequency not reported</b>: Erythema multiforme, severe cutaneous reactions, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Very Common (10% or more): Dizziness (up to 16%), somnolence (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Disturbance in attention, dysgeusia, headache, paresthesia, tremor, vertigo</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyskinesia, extrapyramidal disorder, syncope</p>
<p><b>Rare</b> (less than 0.1%): Convulsion, dystonia, serotonin syndrome</p>
<p><b>Frequency not reported</b>: Seizure<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 15%)</p>
<p><b>Common</b> (1% to 10%): Abnormal dreams, abnormal orgasm, anorgasmia, anxiety, decreased libido, irritability, nervousness, withdrawal syndrome</p>
<p><b>Uncommon</b> (0.1% to 1%): Depersonalization, hypomania</p>
<p><b>Rare</b> (less than 0.1%): Hallucination, mania</p>
<p><b>Frequency not reported</b>: Bruxism, discontinuation syndrome, suicidal thoughts<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Very Common (10% or more): Erectile dysfunction (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Delayed ejaculation, ejaculation disorder, ejaculation failure, proteinuria, sexual dysfunction, urinary hesitation</p>
<p><b>Uncommon</b> (0.1% to 1%): Urinary retention<sup>[Ref]</sup></p><h3>Other</h3><p>Very Common (10% or more): Fatigue (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Asthenia, chills, feeling jittery, tinnitus<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite, decreased weight, elevated fasting triglycerides, elevated LDL cholesterol, elevated total cholesterol, increased blood cholesterol, increased weight</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased blood triglycerides</p>
<p><b>Rare</b> (less than 0.1%): Hyponatremia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Ischemic cardiac adverse reactions, myocardial ischemia, myocardial infarction, and/or coronary occlusion requiring revascularization usually occurred in patients who had multiple underlying cardiac risk factors.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Blood pressure increased, hot flush, increased sustained hypertension, orthostatic hypotension, palpitations, tachycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Peripheral coldness</p>
<p><b>Frequency not reported</b>: Coronary occlusion requiring revascularization, ischemic cardiac adverse reactions, myocardial infarction, myocardial ischemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, mydriasis</p>
<p><b>Frequency not reported</b>: Angle closure glaucoma<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Yawning</p>
<p><b>Uncommon</b> (0.1% to 1%): Epistaxis</p>
<p><b>Frequency not reported</b>: Interstitial lung disease, eosinophilic pneumonia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function test<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal stiffness<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Rare</b> (less than 0.1%): Angioedema<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood prolactin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Abnormal bleeding<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>SSRI’s vs SNRI’s - What's the difference between them?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Khedezla (desvenlafaxine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: serotonin-norepinephrine reuptake inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Khedezla &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Pristiq</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Depression</li>
<li>Major Depressive Disorder</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to desvenlafaxine: oral tablet extended release</i></p><h3>General</h3><p>The most commonly reported side effects were nausea, dry mouth, hyperhidrosis, and dizziness.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Very Common (10% or more): Nausea (up to 36%), dry mouth (up to 25%), constipation (up to 14%)</p><p><b>Common</b> (1% to 10%): Diarrhea, vomiting</p><p><b>Rare</b> (less than 0.1%): Acute pancreatitis</p><p><b>Frequency not reported</b>: Gastrointestinal bleeding<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Very Common (10% or more): Hyperhidrosis (up to 21%)</p><p><b>Common</b> (1% to 10%): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia</p><p><b>Rare</b> (less than 0.1%): Photosensitivity reaction, Stevens-Johnson syndrome</p><p><b>Frequency not reported</b>: Erythema multiforme, severe cutaneous reactions, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Very Common (10% or more): Dizziness (up to 16%), somnolence (up to 12%)</p><p><b>Common</b> (1% to 10%): Disturbance in attention, dysgeusia, headache, paresthesia, tremor, vertigo</p><p><b>Uncommon</b> (0.1% to 1%): Dyskinesia, extrapyramidal disorder, syncope</p><p><b>Rare</b> (less than 0.1%): Convulsion, dystonia, serotonin syndrome</p><p><b>Frequency not reported</b>: Seizure<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 15%)</p><p><b>Common</b> (1% to 10%): Abnormal dreams, abnormal orgasm, anorgasmia, anxiety, decreased libido, irritability, nervousness, withdrawal syndrome</p><p><b>Uncommon</b> (0.1% to 1%): Depersonalization, hypomania</p><p><b>Rare</b> (less than 0.1%): Hallucination, mania</p><p><b>Frequency not reported</b>: Bruxism, discontinuation syndrome, suicidal thoughts<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Very Common (10% or more): Erectile dysfunction (up to 11%)</p><p><b>Common</b> (1% to 10%): Delayed ejaculation, ejaculation disorder, ejaculation failure, proteinuria, sexual dysfunction, urinary hesitation</p><p><b>Uncommon</b> (0.1% to 1%): Urinary retention<sup>[Ref]</sup></p><h3>Other</h3><p>Very Common (10% or more): Fatigue (up to 11%)</p><p><b>Common</b> (1% to 10%): Asthenia, chills, feeling jittery, tinnitus<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Decreased appetite, decreased weight, elevated fasting triglycerides, elevated LDL cholesterol, elevated total cholesterol, increased blood cholesterol, increased weight</p><p><b>Uncommon</b> (0.1% to 1%): Increased blood triglycerides</p><p><b>Rare</b> (less than 0.1%): Hyponatremia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Ischemic cardiac adverse reactions, myocardial ischemia, myocardial infarction, and/or coronary occlusion requiring revascularization usually occurred in patients who had multiple underlying cardiac risk factors.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Blood pressure increased, hot flush, increased sustained hypertension, orthostatic hypotension, palpitations, tachycardia</p><p><b>Uncommon</b> (0.1% to 1%): Peripheral coldness</p><p><b>Frequency not reported</b>: Coronary occlusion requiring revascularization, ischemic cardiac adverse reactions, myocardial infarction, myocardial ischemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, mydriasis</p><p><b>Frequency not reported</b>: Angle closure glaucoma<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Yawning</p><p><b>Uncommon</b> (0.1% to 1%): Epistaxis</p><p><b>Frequency not reported</b>: Interstitial lung disease, eosinophilic pneumonia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function test<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Musculoskeletal stiffness<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Rare</b> (less than 0.1%): Angioedema<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Increased blood prolactin<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Abnormal bleeding<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>SSRI’s vs SNRI’s - What's the difference between them?</li>
</ul><h2>More about Khedezla (desvenlafaxine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: serotonin-norepinephrine reuptake inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Khedezla &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Depression</li>
<li>Major Depressive Disorder</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>